Systemic Delivery of Folate-PEG siRNA Lipopolyplexes with Enhanced Intracellular Stability forIn VivoGene Silencing in Leukemia
- 24 August 2017
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 28 (9) , 2393-2409
Abstract
Protection of small interfering RNA (siRNA) against degradation and targeted delivery across the plasma and endosomal membranes to the final site of RNA interference (RNAi) are major aims for the development of siRNA therapeutics. Targeting for folate receptor (FR)-expressing tumors, we optimized siRNA polyplexes by coformulating a folate-PEG-oligoaminoamide (for surface shielding and targeting) with one of three lipo-oligoaminoamides (optionally tyrosine-modified, for optimizing stability and size) to generate ∼100 nm targeted lipopolyplexes (TLPs), which self-stabilize by cysteine disulfide cross-links. To better understand parameters for improved tumor-directed gene silencing, we analyzed intracellular distribution and siRNA release kinetics. FR-mediated endocytosis and endosomal escape of TLPs was confirmed by immuno-TEM. We monitored colocalization of TLPs with endosomes and lysosomes, and onset of siRNA release by time-lapse confocal microscopy; analyzed intracellular stability by FRET using double-labeled siRNA; and correlated results with knockdown of eGFPLuc protein and EG5 mRNA expression. The most potent formulation, TLP1, containing lipopolyplex-stabilizing tyrosine trimers, was found to unpack siRNA in sustained manner with up to 5-fold higher intracellular siRNA stability after 4 h compared to other TLPs. Unexpectedly, data indicated that intracellular siRNA stability instead of an early endosomal exit dominate as a deciding factor for silencing efficiency of TLPs. After i.v. administration in a subcutaneous leukemia mouse model, TLP1 exhibited ligand-dependent tumoral siRNA retention, resulting in 65% EG5 gene silencing at mRNA level without detectable adverse effects. In sum, tyrosine-modified TLP1 conveys superior protection of siRNA for an effective tumor-targeted delivery and RNAi in vivo.Keywords
Funding Information
- Bayerische Forschungsstiftung
- Deutsche Forschungsgemeinschaft (GZ995, SFB1032/B1, SFB1032/B2)
- Japan Science and Technology Agency
- National Natural Science Foundation of China (GZ995)
- European Molecular Biology Organization
- Eesti Teadusagentuur (PUT1617)
- Haridus- ja Teadusministeerium (0180019s11)
This publication has 81 references indexed in Scilit:
- 5′‐(E)‐Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA–GalNAc ConjugatesChemBioChem, 2016
- Current views on inducing synthetic lethal RNAi responses in the treatment of cancerExpert Opinion on Biological Therapy, 2015
- Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene SilencingJournal of the American Chemical Society, 2014
- Current issues of RNAi therapeutics delivery and developmentJournal of Controlled Release, 2014
- Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modificationsNature Biotechnology, 2014
- siRNA Nanoparticles: The Future of RNAi Therapeutics for Oncology?Nanomedicine, 2014
- First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver InvolvementCancer Discovery, 2013
- Rational design of smart supramolecular assemblies for gene delivery: chemical challenges in the creation of artificial virusesChemical Society Reviews, 2011
- Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticlesNature, 2010
- Small interfering RNA targeting Raf-1 inhibits tumor growth in vitro and in vivoCancer Gene Therapy, 2005